排序方式: 共有12条查询结果,搜索用时 343 毫秒
1.
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
下载免费PDF全文
![点击此处可从《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A. Boswood J. Häggström S.G. Gordon G. Wess R.L. Stepien M.A. Oyama B.W. Keene J. Bonagura K.A. MacDonald M. Patteson S. Smith P.R. Fox K. Sanderson R. Woolley V. Szatmári P. Menaut W.M. Church M. L. O'Sullivan J.‐P. Jaudon J.‐G. Kresken J. Rush K.A. Barrett S.L. Rosenthal A.B. Saunders I. Ljungvall M. Deinert E. Bomassi A.H. Estrada M.J. Fernandez Del Palacio N.S. Moise J.A. Abbott Y. Fujii A. Spier M.W. Luethy R.A. Santilli M. Uechi A. Tidholm P. Watson 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2016,30(6):1765-1779
2.
Frances J. Barr MA VetMB Mark W. Patteson MA Vetmb Vanda M. Lucke BVSc PHD Christine Gibbs BVSc PHD 《Veterinary radiology & ultrasound》1989,30(4):169-173
Persistent hypercalcemia in the dog is most commonly seen as a paraneoplastic syndrome or in association with widespread osteolytic lesions. In high concentrations calcium is a potent nephrotoxin and may cause severe and irreversible renal damage. The ultrasonographic changes in the kidneys of three dogs with hypercalcernic nephropathy are described'and compared with the changes described in the same human condition. It is suggested that ultrasound could be a useful technique for evaluation of the severity of renal damage and the potential return of renal function in such instances. 相似文献
3.
Adrian Boswood Sonya G. Gordon Jens Häggström Martin Vanselow Gerhard Wess Rebecca L. Stepien Mark A. Oyama Bruce W. Keene John Bonagura Kristin A. MacDonald Mark Patteson Sarah Smith Philip R. Fox Karen Sanderson Richard Woolley Viktor Szatmári Pierre Menaut Whitney M. Church M. Lynne O'Sullivan Jean-Philippe Jaudon Jan-Gerd Kresken John Rush Kirstie A. Barrett Steven L. Rosenthal Ashley B. Saunders Ingrid Ljungvall Michael Deinert Eric Bomassi Amara H. Estrada Maria J. Fernandez Del Palacio N. Sydney Moise Jonathan A. Abbott Yoko Fujii Alan Spier Michael W. Luethy Roberto A. Santilli Masami Uechi Anna Tidholm Christoph Schummer Philip Watson 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2020,34(3):1108-1118
4.
5.
N.J. Summerfield A. Boswood M.R. O'Grady S.G. Gordon J. Dukes‐McEwan M.A. Oyama S. Smith M. Patteson A.T. French G.J. Culshaw L. Braz‐Ruivo A. Estrada M.L. O'Sullivan J. Loureiro R. Willis P. Watson 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2012,26(6):1337-1349
6.
J. Häggström A. Boswood M. O'Grady O. Jöns S. Smith S. Swift M. Borgarelli B. Gavaghan J.‐G. Kresken M. Patteson B. Åblad C.M. Bussadori T. Glaus A. Kovačević M. Rapp R.A. Santilli A. Tidholm A. Eriksson M.C. Belanger M. Deinert C.J.L. Little C. Kvart A. French M. Rønn‐Landbo G. Wess A. Eggertsdottir M. Lynne O'Sullivan M. Schneider C.W. Lombard J. Dukes‐McEwan R. Willis A. Louvet R. DiFruscia 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2013,27(6):1441-1451
7.
8.
Häggström J Boswood A O'Grady M Jöns O Smith S Swift S Borgarelli M Gavaghan B Kresken JG Patteson M Ablad B Bussadori CM Glaus T Kovacević A Rapp M Santilli RA Tidholm A Eriksson A Belanger MC Deinert M Little CJ Kvart C French A Rønn-Landbo M Wess G Eggertsdottir AV O'Sullivan ML Schneider M Lombard CW Dukes-McEwan J Willis R Louvet A DiFruscia R 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2008,22(5):1124-1135
Background: Myxomatous mitral valve disease (MMVD) continues to be an important cause of morbidity and mortality in geriatric dogs despite conventional therapy. Hypothesis: Pimobendan in addition to conventional therapy will extend time to sudden cardiac death, euthanasia for cardiac reasons, or treatment failure when compared with conventional therapy plus benazepril in dogs with congestive heart failure (CHF) attributable to MMVD. Animals: Two hundred and sixty client‐owned dogs in CHF caused by MMVD were recruited from 28 centers in Europe, Canada, and Australia. Methods: A prospective single‐blinded study with dogs randomized to PO receive pimobendan (0.4–0.6 mg/kg/d) or benazepril hydrochloride (0.25–1.0 mg/kg/d). The primary endpoint was a composite of cardiac death, euthanized for heart failure, or treatment failure. Results: Eight dogs were excluded from analysis. One hundred and twenty‐four dogs were randomized to pimobendan and 128 to benazepril. One hundred and ninety dogs reached the primary endpoint; the median time was 188 days (267 days for pimobendan, 140 days for benazepril hazard ratio = 0.688, 95% confidence limits [CL] = 0.516–0.916, P= .0099). The benefit of pimobendan persisted after adjusting for all baseline variables. A longer time to reach the endpoint was also associated with being a Cavalier King Charles Spaniel, requiring a lower furosemide dose, and having a higher creatinine concentration. Increases in several indicators of cardiac enlargement (left atrial to aortic root ratio, vertebral heart scale, and percentage increase in left ventricular internal diameter in systole) were associated with a shorter time to endpoint, as was a worse tolerance for exercise. Conclusions and Clinical Importance: Pimobendan plus conventional therapy prolongs time to sudden death, euthanasia for cardiac reasons, or treatment failure in dogs with CHF caused by MMVD compared with benazepril plus conventional therapy. 相似文献
9.
Longitudinal Analysis of Quality of Life,Clinical, Radiographic,Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
下载免费PDF全文
![点击此处可从《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A. Boswood S.G. Gordon J. Häggström G. Wess R.L. Stepien M.A. Oyama B.W. Keene J. Bonagura K.A. MacDonald M. Patteson S. Smith P.R. Fox K. Sanderson R. Woolley V. Szatmári P. Menaut W.M. Church M.L. O'Sullivan J.‐P. Jaudon J.‐G. Kresken J. Rush K.A. Barrett S.L. Rosenthal A.B. Saunders I. Ljungvall M. Deinert E. Bomassi A.H. Estrada M.J. Fernandez Del Palacio N.S. Moise J.A. Abbott Y. Fujii A. Spier M.W. Luethy R.A. Santilli M. Uechi A. Tidholm C. Schummer P. Watson 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2018,32(1):72-85
Background
Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD ) and cardiomegaly have not been described.Objectives
To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF ) or cardiac‐related death (CRD ) in dogs with MMVD and cardiomegaly. To determine whether pimobendan‐treated dogs differ from dogs receiving placebo at onset of CHF .Animals
Three hundred and fifty‐four dogs with MMVD and cardiomegaly.Materials and Methods
Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4–0.6 mg/kg/d) or placebo. Clinical, laboratory, and heart‐size variables in both groups were measured and compared at different time points (day 35 and onset of CHF ) and over the study duration. Relationships between short‐term changes in echocardiographic variables and time to CHF or CRD were explored.Results
At day 35, heart size had reduced in the pimobendan group: median change in (Δ) LVIDDN ?0.06 (IQR : ?0.15 to +0.02), P < 0.0001, and LA :Ao ?0.08 (IQR : ?0.23 to +0.03), P < 0.0001. Reduction in heart size was associated with increased time to CHF or CRD . Hazard ratio for a 0.1 increase in ΔLVIDDN was 1.26, P = 0.0003. Hazard ratio for a 0.1 increase in ΔLA :Ao was 1.14, P = 0.0002. At onset of CHF , groups were similar.Conclusions and Clinical Importance
Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF , dogs treated with pimobendan were indistinguishable from those receiving placebo.10.
J.D. Harris C.J.L. Little J.M. Dennis M.W. Patteson 《Journal of Veterinary Cardiology》2017,19(5):421-432